Rol' i mesto gipoglikemii v upravlenii sakharnym diabetom 2 tipa


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Recurrent hypoglycemia reduces the sensitivity to their timely recognition and can lead to the development of more severe hypoglycemia and hypoglycemic coma. The greatest risk of hypoglycemia occurs in patients receiving insulin and/or sulfonylurea medications. The article presents data from international clinical trials showing efficacy of vildagliptin as monotherapy and in combination with other antihyperglicemic agents. The main benefits of combination therapy with metformin and a dipeptidyl peptidase - 4 inhibitors are discussed. These drugs have simultaneous action on the key links in the pathogenesis of type 2 diabetes mellitus - insulin resistance and dysfunction of islet cells of the pancreas, which makes the high potential of this type of therapy.

全文:

受限制的访问

参考

  1. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
  2. Capone RJ, Pawitan N. Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients. J Am Coll Cardiol 1991;18:1434-58.
  3. Масляева Л.В., Старченко Т.Г. Нарушение ритма и проводимости сердца у больных с гипертонической болезнью и сопутствующим сахарным диабетом 2 типа / Материалы первого всероссийского съезда аритмологов. М., 2005. С. 72-74.
  4. Osgren CJ, et. а. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Obes Metab 2004;6(5):367-74.
  5. Coutinho M, Genstein HC. The relationship between glucose and incident cardiovascular events; met regression analysis of published data from 20 studies of 95783 individuals followed for 12,4 years. Diabetes Care 1999:233-40.
  6. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
  7. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. NEngl J Med 2005;353:2643-53.
  8. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
  9. Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 2002;51:724-33
  10. Gill GV, Woodward A, Casson IF, Weston PJ. Cardiac arrhythmia and nocturnal hypo-glycaemia in type 1 diabetes - the 'dead in bed' syndrome revisited. Diabetologia 2009; 52:42-45.
  11. Радзевич А.Э., Сметнев А.С., Попов В.В. и др. Электрокардиографические маркеры риска внезапной смерти. Влияние ишемии и реваскуляризации миокарда // Кардиология 2001. № 6.C. 99-104.
  12. Puljevic D, Smalclj A, Duracovic Z. QT dispersion, daily variations, and late potentials as risk markers for ventricular tachycardia. Eur Heart J 1997;18(6):1343-49.
  13. Robinson RT, Harris ND, Ireland RH, Macdonald IA, Heller SR. Changes in cardiac repolarization during clinical episodes of nocturnal hypoglycaemia in adults with type 1 diabetes. Diabetologia 2004;47:312-15.
  14. Нестерова И.В. и др. Аритмологическая характеристика больных с хронической сердечной недостаточностью при сохраненном синусовом ритме и подход к ее улучшению // Вестник аритмологии 2003. № 31. С. 20-25.
  15. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann InternMed 2007;147:386-99.
  16. Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events. A comparison of glyburide with other secretagogues and with insulin. Diabetes Care2007;30:389-94.
  17. Fisher M. Hypoglycaemia in patients with type 2 diabetes: minimizing the risk. Br J Diabetes Vasc Dis 2010;10:35-41.
  18. King Н, Aubert RE&Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;1414-31.
  19. Halimi S, Schweizer A, Minic B, et al. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vascular Health Risk Management 2008;4(3):481-92.
  20. Анциферов М.Б. Ингибиторы ДПП-4 в практическом здравоохранении: опыт Москвы / Материалы конгресса «Эндокринология столицы», 28.10.2012.
  21. Croxtall JD, Keam SJ. Vildagliptin: a review of use in the management of type 2 diabetes mellitus. Drugs 2008;68(16):2387-409.
  22. Migoya EM, et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010;88(6):801-08.
  23. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011;14:665-71.
  24. Brod M, Christensen T, Bushnell DM. Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: resultsfrom a four-country survey. J Med Econ 2012;15:77-86.
  25. Сахарный диабет 2 типа: проблемы и решения / Под редакцией А.С. Аметова. 2-е изд., перераб. и доп. М., 2013.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2013
##common.cookie##